XBI icon

SPDR S&P Biotech ETF

702 hedge funds and large institutions have $6.3B invested in SPDR S&P Biotech ETF in 2022 Q2 according to their latest regulatory filings, with 121 funds opening new positions, 249 increasing their positions, 196 reducing their positions, and 110 closing their positions.

Holders
702
Holders Change
+3
Holders Change %
+0.43%
% of All Funds
11.87%
Holding in Top 10
32
Holding in Top 10 Change
+12
Holding in Top 10 Change %
+60%
% of All Funds
0.54%
New
121
Increased
249
Reduced
196
Closed
110
Calls
$1.8B
Puts
$1.78B
Net Calls
+$26.7M
Net Calls Change
-$52.4M
Name Market Value Shares Shares
Change
Shares
Change %
IC
826
Ikarian Capital
Texas
VCIM
827
Velan Capital Investment Management
Georgia
CM
828
Capula Management
Cayman Islands
JCI
829
Jet Capital Investors
New York
SGM
830
Skye Global Management
Florida
PCM
831
Prelude Capital Management
New York
AFM
832
Anson Funds Management
Texas
BSCM
833
Berry Street Capital Management
United Kingdom
BM
834
Baymount Management
Florida
SM
835
Scoggin Management
New York
Squarepoint
836
Squarepoint
New York
GTC
837
Ghost Tree Capital
New York
SPPAM
838
Summit Partners Public Asset Management
Massachusetts
HM
839
HealthCor Management
New York
SCM
840
Silverarc Capital Management
Massachusetts
SC
841
Shay Capital
New York
CA
842
CHI Advisors
New York
SCM
843
Soleus Capital Management
Connecticut
MCM
844
Masters Capital Management
Georgia
BFM
845
Boothbay Fund Management
New York
ACM
846
Aquilo Capital Management
California
PA
847
Perceptive Advisors
New York
BCM
848
Bronte Capital Management
Australia
Marshall Wace
849
Marshall Wace
United Kingdom
CL
850
CSS LLC
Illinois